TKT and retinoblastoma: Ji et al. [19] suggested that hTERT promoter-driven oncolytic CRAd vector in combination with HSV tk /GCV gene therapy could effectively reduce growth of human retinoblastoma in an orthotopic nude mouse model but not in primary human retinal pigment epithelial cells (hRPE).